Citations

Clear

3042 citation(s) found for "Kumar, S".

Short‐term outcomes of atrial flutter ablation
Tripathi, Byomesh , Arora, Shilpkumar , Mishra, Abhishek , Kundoor, Vishwa, Lahewala, Sopan , Kumar, Varun , Shah, Mahek , Lakhani, Dhairya A. , Shah, Harshil , Patel, Nilay , Patel, Nileshkumar , Dave, Mihir, Deshmukh, Abhishek , Sattur, Sudhakar, Gopalan, Radha , Lakhani, Dhairya

Mayo Clinic

Journal of Cardiovascular Electrophysiology | August 11, 2017 | Volume: 28 | Issue: 11 | Pages: 1275-1284

10.1111/jce.13311 | PMID 28800179 Get It

AbstractBackgroundUnderstanding the factors associated with early readmissions following atrial flutter (AFL) ablation is critical to reduce the cost and improving the quality of life in AFL patients.MethodThe study cohort was derived from the national readmission database 2013–2014. International Classification of Diseases, 9th Revision (ICD‐9‐CM) diagnosis code 427.32 and procedure code 37.34 were used to identify AFL and catheter ablation, respectively. The primary and secondary outcomes were 90‐day readmission and complications including in‐hospital mortality. Cox proportional regression and hierarchical logistic regression were used to generate the predictors of primary and secondary outcomes respectively. Readmission causes were identified by ICD‐9‐CM code in primary diagnosis field of readmissions.ResultReadmission rate of 18.19% (n = 1,010 with 1,396 readmissions) was noted among AFL patients (n = 5552). Common etiologies for readmission were heart failure (12.23%), atrial fibrillation (11.13%), atrial flutter (8.93%), respiratory complications (9.42%), infections (7.4%), bleeding (7.39%, including GI bleed–4.09% and intracranial bleed–0.79%) and stroke/TIA (1.89%). Multivariate predictors of 90‐day readmission (hazard ratio, 95% confidence interval, P value) were preexisting heart failure (1.30, 1.13–1.49, P < 0.001), chronic pulmonary disease (1.37, 1.18–1.58, P < 0.001), anemia (1.23, 1.02–1.49, P = 0.035), malignancy (1.87, 1.40–2.49, P < 0.001), weekend admission compared to weekday admission (1.23, 1.02–1.47, P = 0.029), and length of stay (LOS) ≥5 days (1.39, 1.16–1.65, P < 0.001). Note that 50% of readmissions happened within 30 days of discharge.ConclusionCardiac etiologies remain the most common reason for the readmission after AFL ablation. Identifying high risk patients, careful discharge planning, and close follow‐up postdischarge can potentially reduce readmission rates in AFL ablation patients.
Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials
Lakshman, Arjun , Abeykoon, Jithma P. , Kumar, Shaji , Dingli, David , Gonsalves, Wilson I. , Leung, Nelson , Kourelis, Taxiarchis , Go, Ronald S. , Lacy, Martha Q. , Hobbs, Miriam, Lin, Yi , Warsame, Rahma , Lust, John A., Fonder, Amie , Hwa, Yi L. , Hayman, Suzanne R. , Russell, Stephen J. , Kyle, Robert A. , Kapoor, Prashant , Buadi, Francis K. , Gonsalves, Wilson , Leung, Nelson , Kourelis, Taxiarchis V, Go, Ronald S , Warsame, Rahma , Lust, John, Fonder, Amie L, Lakshman, Arjun , Russell, Stephen J , Dingli, David , Lin, Yi , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | August 11, 2017 | Volume: 92 | Issue: 11 | Pages: 1146-1155

10.1002/ajh.24883 | PMID 28799231 Get It

AbstractOutside of clinical trials, experience with daratumumab‐based combination therapies (DCTs) using bortezomib (V)/lenalidomide (R)/pomalidomide (P), and dexamethasone (d) in relapsed/refractory multiple myeloma (RRMM) is limited. We reviewed the outcomes of 126 patients who received ≥ 1 cycle of any DCT. Median age at DCT initiation was 67 (range, 43‐93) years. High‐risk cytogenetics was present in 33% patients. Median number of prior therapies was 4 (range, 1‐14) and time to first DCT from diagnosis was 4.3 years (range, 0.4‐13.0). Seventeen (13%) patients were refractory to single agent daratumumab. Fifty‐two (41%), 34 (27%), 23 (18%), and 17 (14%) received DPd, DRd, DVd and “other” DCTs, respectively. Overall response rate was 47%. Median follow‐up was 5.5 months (95% CI, 4.2‐6.1). Median progression‐free survival (PFS) was 5.5 months (95% CI, 4.2‐7.8). Median overall survival was not reached (NR) with any regimen. Median PFS (months) was worst for penta‐refractory MM (n = 8) vs quadruple refractory MM (n = 18) and others (n = 100) (2.2 [95% CI, 1‐2.4] vs 3.1 [95% CI, 2.1‐NR] vs 5.9 [95% CI, 5.0‐NR]; P < .001); those who were refractory to ≥1 agents used in the DCT vs others (4.9 [95% CI, 3.1‐6.0] vs 8.2 [95% CI, 4.6‐NR]; P = .02); and those who received >2 prior therapies vs others (5.0 months [95% CI, 3.7‐5.9] vs NR [95% CI, NR‐NR]; P = .002). Non‐hematologic toxicities included infections (38%), fatigue (32%), and infusion reactions (18%). Grade 3 or higher hematological toxicities were seen in 41% of patients. DCTs are effective in RRMM. ORR and PFS in heavily pretreated patients are lower than those reported in clinical trials.
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia
Paludo, Jonas , Abeykoon, Jithma P. , Kumar, Shaji , Shreders, Amanda , Kourelis, Taxiarchis , King, Rebecca L. , Reeder, Craig B. , Kyle, Robert A. , Dingli, David , Lacy, Martha Q. , Lin, Yi , Warsame, Rahma , Lust, John A., Ansell, Stephen M. , Kapoor, Prashant , Buadi, Francis K. , Gonsalves, Wilson , Paludo, Jonas , Dingli, David , Lin, Yi , Ailawadhi, Sikander , Gertz, Morie A. , Leung, Nelson , Habermann, Thomas M. , Witzig, Thomas E. , Dispenzieri, Angela , Go, Ronald S. , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Mayo Clinic

British Journal of Haematology | August 8, 2017 | Volume: 179 | Issue: 1 | Pages: 98-105

10.1111/bjh.14826 | PMID 28786474 Get It

SummaryThe management of Waldenström macroglobulinaemia (WM) relies predominantly on small trials, one of which has demonstrated activity of dexamethasone, rituximab and cyclophosphamide (DRC) in the frontline setting. We report on the efficacy of DRC, focusing on relapsed/refractory (R/R) patients. Ibrutinib, a recently approved agent in WM demonstrated limited activity in patients with MYD88WT genotype. Herein, we additionally report on the activity of DRC based on the MYD88L265P mutation status. Of 100 WM patients evaluated between January 2007 and December 2014 who received DRC, 50 had R/R WM. The overall response rate (ORR) was 87%. The median progression‐free survival (PFS) and time‐to‐next‐therapy (TTNT) were 32 (95% confidence interval [CI]: 15–51) and 50 (95% CI: 35–60) months, respectively. In the previously untreated cohort (n = 50), the ORR was 96%, and the median PFS and TTNT were 34 months (95% CI: 23–not reached [NR]) and NR (95% CI: 37–NR), respectively. Twenty‐five (86%) of 29 genotyped patients harbored MYD88L265P. The response rates and outcomes were independent of MYD88 mutation status. Grade ≥3 adverse effects included neutropenia (20%), thrombocytopenia (7%) and infections (3%). Similar to the frontline setting, DRC is an effective and well‐tolerated salvage regimen for WM. In contrast to ibrutinib, DRC offers a less expensive, fixed‐duration option, with preliminary data suggesting efficacy independent of the patients’ MYD88 status.
Abstract 3537: Otx2 and c-Myc association drives tumor progression in medulloblastoma molecular subtypes 3/4
Guda, Maheedhara R. , Asuthkar, Swapna , Purvis, Ian J. , Martin, Sarah E. , Tsung, Andrew J. , Velpula, Kiran Kumar , Lu, Yining , Labak, Collin M. , Jain, Neha , Daniels, David J.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 3537-3537

10.1158/1538-7445.am2017-3537 Get It

Abstract Medulloblastoma (MB) is a pediatric brain tumor comprising of four molecular subgroups, with Group 3 and 4 tumors characterized by particularly poor prognosis. While research has advanced our understanding of MB, there is still a pressing need for new knowledge of the functional processes underlying its progression due to a scarcity of therapeutics. Recent studies have identified Orthodenticle homeobox 2 (Otx2), a cerebellar transcription factor, to be highly expressed in MB Group 3/4 subtypes. Datamining studies from Northcott and Robinson datasets revealed co-expression of Otx2 and c-Myc in Group 3/4 tumors. DAB staining conducted in human MB specimens showed increased expression of Otx2 and c-Myc. Colocalization studies confirmed datamining results. Next, we used a clinical Otx2 inhibitor, all-trans retinoic acid (ATRA), in a PDX cell line, P9, and in UW228 cells. Western blot analysis demonstrated reduced levels of c-Myc along with Otx2. In another experiment, we used the c-Myc/Max inhibitor 10058-F4 and observed comparable results to Otx2 inhibition. Real time PCR and immunocytochemistry experiments confirmed the aforementioned results. Further, treatment with ATRA and 10058-F4 showed reduced proliferation and migratory abilities in p9 and UW228 when compared to their respective controls. Mass spectrometry conducted on immune-precipitated Otx2 in P9 cells revealed a plethora of novel interaction partners that drive tumor growth and progression. In addition, western blot analysis in ATRA treated cells showed reduced expression of Max, suggestive of the existence of a feedback loop that link with Otx2 and c-Myc. Collectively our studies highlight Otx2 as a potential contributor to the malignant phenotype and describe its role in mediating the aggressiveness of Group 3/4 medulloblastoma. Citation Format: Yining Lu, Maheedhara R. Guda, Swapna Asuthkar, Ian Purvis, Collin M. Labak, Neha Jain, David J. Daniels, Sarah E. Martin, Andrew J. Tsung, Kiran K. Velpula. Otx2 and c-Myc association drives tumor progression in medulloblastoma molecular subtypes 3/4 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3537. doi:10.1158/1538-7445.AM2017-3537
Abstract 2004: Epigenetic targeting of CD276 expression in medullolbastoma
Guda, Maheedhara R. , Castellanos, Jose R., Sanam, Ramadevi, Martin, Sarah E. , Lin, Julian , Tsung, Andrew J. , Velpula, Kiran Kumar , Asuthkar, Swapna , Labak, Collin M. , Daniels, David J.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 2004-2004

10.1158/1538-7445.am2017-2004 Get It

Abstract Medulloblastoma (MB) is the most common malignant brain tumor in children and accounts for 20% of pediatric CNS tumors. Following surgery and treatment with chemotherapy and radiation, MBs recur in a significant proportion of patients. Moreover, survivors experience comorbidities related to the tumor and/or its treatment. New insights into MB tumor pathogenesis are needed for improving the survivorship and outcome of MB. Epigenetic silencing, including histone modification and DNA methylation, is an important tumorigenic mechanism in MB. However, its role in cancer immunopathology is poorly understood. Using datamining and immunohistochemistry analysis, we show that B7-H3 (CD276), an important immune checkpoint member of the B7 and CD28 families, is highly upregulated in all four molecular subtypes of MB compared to normal tissue. Based on the clinical success of inhibitory immune checkpoint blockades (CTLA-4, PD-1, and PD-L1), CD276 appears to be a promising therapeutic target for cancer immunotherapy. Moreover, we observed that increased expression of CD276 correlates significantly with the expression of Enhancer of Zeste Homologue 2 (EZH2), a histone H3-methylating (H3K27me3) catalytic subunit in the human MB specimens. We hypothesize that combined targeting of CD276 and EZH2 may have greater impact on tumor progression and immune cell response in MB. Simultaneously, we performed LC/MS analysis to identify novel interaction partners of CD276 in MB tumor. These findings taken together suggest that CD276 is strongly associated with several epigenetic markers, indicating a strong relationship between cancer immune evasion and epigenetic mechanisms. Citation Format: Maheedhara R. Guda, Jose R. Castellanos, Collin M. Labak, Ramadevi Sanam, David J. Daniels, Sarah E. Martin, Julian J. Lin, Andrew J. Tsung, Kiran K. Velpula, Swapna Asuthkar. Epigenetic targeting of CD276 expression in medullolbastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2004. doi:10.1158/1538-7445.AM2017-2004
Abstract 1319: Epigenome-wide association study reveals differential DNA methylation consistent with progression of multiple myeloma
Gragg, Stephen D., Absher, Devin , Pillion, Christina, Myers, R , Kumar, Shaji , Vachon, Celine M. , Brown, Elizabeth , Cui, Xiangqin , Costa, Luciano J. , Chiu, Brian C.‐H. , Vachon, Celine M.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 1319-1319

10.1158/1538-7445.am2017-1319 Get It

Abstract Purpose: Multiple myeloma (MM) is the second most common hematological malignancy in the US. It is characterized by a clonal expansion of plasma cells in the bone marrow and extramedullary sites and is preceded by two precursor conditions including monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM). Strong evidence suggests a germline and environmental etiology. However, efforts to characterize heritable changes in gene activity, such as DNA methylation, have not been widely reported. Methods: We examined epigenome-wide DNA methylation as markers of MGUS, SMM and MM in peripheral blood obtained from treatment-naïve European American cases with heavy-chain IgG or IgA MGUS (n=60), SMM (n=31) and MM (n=54) and age- and sex-matched controls (n=79) included from the University of Alabama at Birmingham, University of Chicago and the Mayo Clinic, Rochester [54.5% males; mean age, 64 years (range, 36 to 86)]. We quantified DNA methylation of over 450,000 CpG and non-CpG loci using the Infinium HumanMethylation450 array (Illumina). Differentially methylated positions were calculated using a general linear model framework adjusted for confounders and cellular heterogeneity. Results: A total of 6 CpGs were differentially methylated in MM cases compared to controls at a level of genome-wide statistical significance. MM was associated with hypomethylation at differentially methylated positions inside SBNO2 (P=3.37x10-10), WIZ (P=1.12x10-8), CA6 (P=4.29x10-8) and ADORA1 (P=3.68x10-8) as well as intergenic positions proximal to TNFRSF8 (Chr 1p36.22; P=2.24x10-9) and ENDOV (Chr 17q25.3; P=2.74x10-8). Each of these loci, with the exception of CA6 and ADORA1, were hypomethylated in each of the 3 plasma cell dyscrasia phenotypes including MGUS and SMM and MM cases compared to controls (P&lt;0.03), albeit not at a level of genome-wide statistical significance. Conclusions: These preliminary findings suggest that differences in DNA methylation may contribute to altered risk of MM, as well as its precursor conditions, and may play a role in plasma cell dyscrasia progression as a consequence of heritable changes in gene activity due to past exposures. Replication in a large yet similarly well-characterized population is warranted. Citation Format: Stephen D. Gragg, Devin Absher, Xiangqin Cui, Christina Pillion, Richard Myers, Shaji Kumar, Luciano Costa, Brian Chiu, Celine Vachon, Elizabeth Brown. Epigenome-wide association study reveals differential DNA methylation consistent with progression of multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1319. doi:10.1158/1538-7445.AM2017-1319
New-Onset Heart Failure and Mortality in Hospital Survivors of Sepsis-Related Left Ventricular Dysfunction
Vallabhajosyula, Saraschandra , Geske, Jeffrey B. , Sakhuja, Ankit , Singhal, Akhil, Poterucha, Joseph T., Murphy, Joseph G. , Jentzer, Jacob C. , Kumar, Mukesh , Kashani, Kianoush , Gajic, Ognjen , Kashyap, Rahul , Vallabhajosyula, Saraschandra , Geske, Jeffrey B

Mayo Clinic

Shock | July 20, 2017 | Volume: 49 | Issue: 2 | Pages: 144-149

10.1097/shk.0000000000000952 | PMID 28727607 Get It

Abstract Background: The association between new-onset left ventricular (LV) dysfunction during sepsis with long-term heart failure outcomes is lesser understood. Methods: Retrospective cohort study of all adult patients with severe sepsis and septic shock between 2007 and 2014 who underwent echocardiography within 72 h of admission to the intensive care unit. Patients with prior heart failure, LV dysfunction, and structural heart disease were excluded. LV systolic dysfunction was defined as LV ejection fraction <50% and LV diastolic dysfunction as ≥grade II. Primary composite outcome included new hospitalization for acute decompensated heart failure and all-cause mortality at 2-year follow-up. Secondary outcomes included persistent LV dysfunction, and hospital mortality and length of stay. Results: During this 8-year period, 434 patients with 206 (48%) patients having LV dysfunction were included. The two groups had similar baseline characteristics, but those with LV dysfunction had worse function as demonstrated by worse LV ejection fraction, cardiac index, and LV diastolic dysfunction. In the 331 hospital survivors, new-onset acute decompensated heart failure hospitalization did not differ between the two cohorts (15% vs. 11%). The primary composite outcome was comparable at 2-year follow-up between the groups with and without LV dysfunction (P = 0.24). Persistent LV dysfunction was noted in 28% hospital survivors on follow-up echocardiography. Other secondary outcomes were similar between the two groups. Conclusions: In patients with severe sepsis and septic shock, the presence of new-onset LV dysfunction did not increase the risk of long-term adverse heart failure outcomes.
Using whole‐exome sequencing to investigate the genetic bases of lysosomal storage diseases of unknown etiology
Wang, Nan , Zhang, Yeting , Gedvilaite, Erika , Loh, Jui Wan , Lin, Timothy, Liu, Xiuping , Liu, Chang‐Gong, Kumar, Dibyendu , Donnelly, Robert, Raymond, Kimiyo , Schuchman, Edward H. , Sleat, David E. , Lobel, Peter , Xing, Jinchuan

Mayo Clinic

Human Mutation | July 13, 2017 | Volume: 38 | Issue: 11 | Pages: 1491-1499

10.1002/humu.23291 | PMID 28703315 Get It